Introduction <p>Premenstrual dysphoric disorder (PMDD) is a syndrome marked by severe mood and physical symptoms during the menstrual luteal phase. This study aimed to evaluate the validity and reliability of the Turkish CTDP-DSM-5 (CTDP-TR), developed by Aperribai et al. (2016), in response to the insufficient diagnosis of PMDD in clinical settings, as per the DSM-5 or ICD-11.</p> Methods <p>Data were collected from women through an electronic questionnaire. A total of 336 participants were included in the analysis. The Patient Health Questionnaire-9 (PHQ-9), Generalized Anxiety Disorder-7 (GAD-7), and Premenstrual Symptoms Screening Tool (PSST) scales were administered alongside the CTDP-TR; the data were analyzed for construct validity, internal consistency, test–retest reliability, convergent validity, and criterion validity.</p> Results <p>The CTDP-TR is a 25-item screening tool based on DSM-5. Confirmatory factor analysis of the CTDP-TR revealed a two-factor structure with acceptable fit indices (CFI = 0.903; TLI = 0.888; RMSEA = 0.057, SRMR = 0.056, χ2/df = 2.08, <i>p</i> &lt; 0.001). The total score of the scale demonstrated excellent internal consistency (α = 0.89), a strong correlation with PSST (<i>r</i> = 0.715), and excellent discrimination in ROC analysis (AUC = 0.943). CTDP-TR scores correlated significantly with PHQ-9 (<i>r</i> = 0.547) and GAD-7 scores (<i>r</i> = 0.510), effectively distinguishing individuals with depression from those without (Cohen's d = 1.171) and individuals with anxiety from those without (Cohen's d = 1.145). The rate of positive screening for PMDD was 43.5%.</p> Conclusions <p>The CTDP-TR is a straightforward, valid, and reliable screening tool aligned with DSM-5 for PMDD in Turkiye, providing a basis for early identification and referral, rather than a stand-alone diagnosis. The existence of this scale is crucial for public health, as it addresses the absence of a standard, DSM-5-oriented tool for PMDD screening in Turkiye.</p>

错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

Psychometric properties of the Turkish version of the premenstrual dysphoric disorder questionnaire for DSM-5 (CTDP–DSM–5)

  • Şükrü Alperen Korkmaz,
  • Hülya Ertekin,
  • Senem Yapar,
  • Leire Aperribai

摘要

Introduction

Premenstrual dysphoric disorder (PMDD) is a syndrome marked by severe mood and physical symptoms during the menstrual luteal phase. This study aimed to evaluate the validity and reliability of the Turkish CTDP-DSM-5 (CTDP-TR), developed by Aperribai et al. (2016), in response to the insufficient diagnosis of PMDD in clinical settings, as per the DSM-5 or ICD-11.

Methods

Data were collected from women through an electronic questionnaire. A total of 336 participants were included in the analysis. The Patient Health Questionnaire-9 (PHQ-9), Generalized Anxiety Disorder-7 (GAD-7), and Premenstrual Symptoms Screening Tool (PSST) scales were administered alongside the CTDP-TR; the data were analyzed for construct validity, internal consistency, test–retest reliability, convergent validity, and criterion validity.

Results

The CTDP-TR is a 25-item screening tool based on DSM-5. Confirmatory factor analysis of the CTDP-TR revealed a two-factor structure with acceptable fit indices (CFI = 0.903; TLI = 0.888; RMSEA = 0.057, SRMR = 0.056, χ2/df = 2.08, p < 0.001). The total score of the scale demonstrated excellent internal consistency (α = 0.89), a strong correlation with PSST (r = 0.715), and excellent discrimination in ROC analysis (AUC = 0.943). CTDP-TR scores correlated significantly with PHQ-9 (r = 0.547) and GAD-7 scores (r = 0.510), effectively distinguishing individuals with depression from those without (Cohen's d = 1.171) and individuals with anxiety from those without (Cohen's d = 1.145). The rate of positive screening for PMDD was 43.5%.

Conclusions

The CTDP-TR is a straightforward, valid, and reliable screening tool aligned with DSM-5 for PMDD in Turkiye, providing a basis for early identification and referral, rather than a stand-alone diagnosis. The existence of this scale is crucial for public health, as it addresses the absence of a standard, DSM-5-oriented tool for PMDD screening in Turkiye.